Image

Middle East and Africa Lentiviral Vector Market – Industry Trends and Forecast to 2028

  • Healthcare
  • Published Report
  • Jun 2021
  • MEA
  • 350 Pages
  • No of Tables: 137
  • No of Figures: 52

Middle East and Africa Lentiviral Vector Market, By Component  (Lentiviral Promoter, Lentiviral Fusion Tags, Lentiviral Packaging Systems, Other), Type (Product, Services), Generation (4th-Generation, 3rd-Generation, 2nd-Generation, 1st-Generation), Workflow (Upstream Processing, Downstream Processing), Delivery Method (In Vivo, Ex Vivo), Disease Indication (Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease, Other), Application (Gene Therapy, Vaccinology), End User (Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, Contract Development and Manufacturing Organization (CDMO), Academic/ Research Institutes), Country(South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa)Industry Trends and Forecast 2028

Middle East and Africa Lentiviral Vector Market

Market Analysis and Insights: Middle East and Africa Lentiviral Vector Market

The lentiviral vector market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.1% in the forecast period of 2021 to 2028 and is expected to reach USD 207.37 million by 2028. Growing demand for lentiviral vector and rise in infectious disease; are the major drivers which propelled the demand of the market in the forecast period.

Lentiviral vectors (LV) are efficient vehicles for gene transfer in mammalian cells due to their capacity to stably express a gene of interest in non-dividing and dividing cells. Lentiviruses are human and animal pathogens that are known to have long incubation periods and persistent infection. The time between the initial infection and the appearance of the first symptoms can reach several months or years.

Molecular biologists frequently use viral vectors to deliver genetic material into cells. This procedure can be carried out in vivo (inside a living organism) or in cell culture (in vitro). Viruses have developed specialized molecular mechanisms to transport their genomes efficiently inside the cells they infect.

Growing geriatric population and demand for vaccine developments during this Covid-19 emergence effectively help the growth of the Lentiviral Vector market. However, the lack of scalability and limitations of downstream purification of lentiviral vectors may hamper the future growth of a Lentiviral Vector market. The strategic initiatives by major market players and rise in funding for genomics act as opportunity for the growth of Asia-Pacific Lentiviral Vector market. The stringent regulatory policies and side effects associated with lentiviral vector products act as challenge for future market growth.

The lentiviral vector market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Lentiviral Vector Market

Middle East and Africa Lentiviral Vector Market Scope and Market Size

The lentiviral vector market is segmented into eight notable segments which are based on the component, type, generation, workflow, delivery method, disease indication, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of component, the lentiviral vector market is segmented into lentiviral promoter, lentiviral fusion tags, lentivirus packaging systems and other. In 2021, lentivirus packaging system segment is expected to dominate the lentiviral vector market due to rising healthcare expenditure.
  • On the basis of type, the lentiviral vector market is segmented into product and services. In 2021, product segment is expected to dominate the lentiviral vector market due to high incidence of genetic diseases.
  • On the basis of generation, the lentiviral vector market is segmented into 4th-generation, 3rd-generation, 2nd-generation and 1st-generation.In 2021, 4th generation segment is expected to dominate the lentiviral vector market due to vigorous research and development activities.
  • On the basis of workflow, the lentiviral vector market is segmented into upstream processing and downstream processing.In 2021, upstream processing segment is expected to dominate the lentiviral vector market due to advancement in technology.
  • On the basis of delivery method, the lentiviral vector market is segmented into in vivo and ex vivo. In 2021, in vivo segment is expected to dominate the lentiviral vector market due to better efficiency.
  • On the basis of disease indication, the lentiviral vector market is segmented into cancer, genetic disorders, infectious diseases, veterinary disease and other. In 2021, cancer segment is expected to dominate the lentiviral vector market due to rising geriatric and cancer cases in Middle East and Africa region.
  • On the basis of application, the lentiviral vector market is segmented into gene therapy and vaccinology.In 2021, gene therapy segment is expected to dominate the lentiviral vector market due to growing awareness of gene therapy and rising clinical trial approval.
  • On the basis of end user, the lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to rising government funds for gene therapy research and development department.

Lentiviral Vector Market Country Level Analysis

The lentiviral vector market is analysed and market size information is provided by the country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.

The countries covered in the lentiviral vector market report are the Saudi Arabia, South Africa, UAE, Israel, Egypt, rest of Middle East and Africa.

Upstream processing segment in Middle East and Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of rising investments for research activities. South Africa is leading the growth of the Middle East and Africa market and up-stream processing segment is dominating in this region due to rising funding by government for technological improvements in R & D activities.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Lentiviral Vector Market 

Lentiviral vector market also provides you with detailed market analysis for every country growth. Moreover, it provides detail data regarding growth in lentiviral vector sales, partnership, acquisition, distribution agreement among the market players of Asia-Pacific region. The data is available for historic period 2010 to 2019. 

Competitive Landscape and Lentiviral Vector Market Share Analysis

Lentiviral Vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to lentiviral vector market.

The major companies which are dealing in the lentiviral vector market report are Merck KGaA, Sirion-Biotech GmbH, Thermo Fisher Scientific Inc., Applied Biological Materials Inc., Creative Biolabs, System Biosciences, LLC, Takara Bio Inc., OriGene Technologies, Inc., Sino Biological, Inc., Lonza, among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the lentiviral vector market.

For instance,

  • In February 2021, Thermo Fisher Scientific Inc. announced that it had won six awards in the annual CMO Leadership Awards. The awards presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition is anticipated to strengthen its footprints globally and lead to an upsurge in its growth in the coming years.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company footprints in the lentiviral vector market which also provides the benefit for organization’s profit growth.

Customization Available: Middle East and Africa Lentiviral Vector Market  

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.  


SKU-

TABLE 1 THERMO FISHER SCIENTIFIC

TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN

TABLE 3 KERAFAST

TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.

TABLE 5 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 62 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 63 SOUTH AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 64 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 SOUTH AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 67 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 68 SOUTH AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 69 SOUTH AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 70 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 71 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 72 SOUTH AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 73 SOUTH AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 74 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 75 SOUTH AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 76 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 78 SAUDI ARABIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 79 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 82 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 87 SAUDI ARABIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 88 SAUDI ARABIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 89 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 90 SAUDI ARABIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 91 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 U.A.E. LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 93 U.A.E. LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 94 U.A.E. LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 95 U.A.E. PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 96 U.A.E. LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 97 U.A.E. LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 98 U.A.E. UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 99 U.A.E. DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 100 U.A.E. LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 101 U.A.E. LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 102 U.A.E. GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 103 U.A.E. INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 104 U.A.E. LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 105 U.A.E. GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 106 U.A.E. LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 107 EGYPT LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 108 EGYPT LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 109 EGYPT LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 EGYPT PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 EGYPT LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 112 EGYPT LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 113 EGYPT UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 114 EGYPT DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 115 EGYPT LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 116 EGYPT LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 117 EGYPT GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 118 EGYPT INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 119 EGYPT LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 120 EGYPT GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 121 EGYPT LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 122 ISRAEL LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 123 ISRAEL LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 124 ISRAEL LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 125 ISRAEL PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 126 ISRAEL LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 127 ISRAEL LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 128 ISRAEL UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 129 ISRAEL DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 130 ISRAEL LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 131 ISRAEL LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 132 ISRAEL GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 133 ISRAEL INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 134 ISRAEL LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 135 ISRAEL GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 136 ISRAEL LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 REST OF MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions